Onkológia 3/2014

Chromosomal rearrangements in lung adenocarcinoma – new treatment options

Chromosomal rearrangements resulting in gene fusions are frequently involved in carcinogenesis. Until recently, their presence was limited on hematologic and mesenchymal neoplasms. However, recent studies have demonstrated that epithelial malignancies can also harbor recurrent gene fusions. Rearrangement of ALK gene (anaplastic lymphoma kinase) defines a molecular subtype of NSCLC with significant therapeutic response to ALK inhibitor crizotinib. Recently been identified rearrangements of ROS1 and RET genes which represent new molecular subtype of lung adenocarcinoma. Given to intensive research of these tyrosine kinase inhibitors, we can expect that will be implemented in routine clinical care in the near future.

Keywords: ALK, ROS1, RET, tyrosine kinase inhibitors.